Evidence map›Paper›PMID 34974810›Full record

ArticleEpigenetics2022

DNA hypermethylation of

Natália Birknerová, Helena Kovaříková, Ivana Baranová, Albína Přikrylová, Jan Laco, Hana Vošmiková, Barbora Gajdošová, Miroslav Hodek, Milan Vošmik, Vladimír Palička and 1 more

Open access · greenAbstract read
In one paragraph

Article in Epigenetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Natália BirknerováDepartment of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.ORCID 0000-0002-2006-6694
Helena KovaříkováDepartment of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.ORCID 0000-0001-5040-4140
Ivana BaranováDepartment of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.ORCID 0000-0001-8273-2595
Albína PřikrylováDepartment of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.
Jan LacoThe Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.ORCID 0000-0002-9602-7501
Hana VošmikováThe Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.ORCID 0000-0001-8595-3991
Barbora GajdošováThe Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.
Miroslav HodekDepartment of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.ORCID 0000-0002-4520-2824
Milan VošmikDepartment of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.ORCID 0000-0001-6497-7505
Vladimír PaličkaDepartment of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.ORCID 0000-0001-7236-1647
Marcela ChmelařováDepartment of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.
Charles University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, an increasing incidence of HPV-induced oropharyngeal squamous cell carcinoma (OPSCC) has been observed. Moreover, locoregionally advanced stages require a combined modal approach, and the prognosis is poor. Therefore, it is essential to find early diagnostic and prognostic biomarkers. DNA methylation changes play a crucial role in the process of carcinogenesis and are often investigated as promising biomarkers in many types of cancer. For analysis of DNA methylation levels of selected tumour suppressor genes in HPV-positive and HPV-negative samples (including primary tumours and corresponding metastases of metastasizing OPSCCs, primary tumours of non-metastasizing OPSCCs, and control samples), methylation-specific MLPA and methylation-specific high-resolution melting analyses were used. A significant difference in methylation between OPSCCs and the control group was observed in

Indexed as

AlphapapillomavirusHead and Neck NeoplasmsOropharyngeal NeoplasmsPapillomavirus InfectionsCell Adhesion Molecule-1DNADNA MethylationHumansPapillomaviridaePAX5 Transcription FactorPAX6 Transcription FactorPrognosisReceptors, Retinoic AcidSquamous Cell Carcinoma of Head and NeckWT1 ProteinsCADM1 protein, humanCell Adhesion Molecule-1DNAPAX5 protein, humanPAX5 Transcription FactorPAX6 protein, humanPAX6 Transcription FactorReceptors, Retinoic Acidretinoic acid receptor betaWT1 protein, humanWT1 ProteinsBiomarkerDNA methylationepigeneticshead and neck cancerhuman papillomavirusoropharyngeal cancer

Identifiers

PMID34974810
PMCPMC9624252
OpenAlexW4205469805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.